These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 10190791)
21. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Amato RJ; Hernandez-McClain J; Henary H Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583 [TBL] [Abstract][Full Text] [Related]
22. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E; Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865 [TBL] [Abstract][Full Text] [Related]
23. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Berry W; Friedland D; Fleagle J; Jackson D; Ilegbodu D; Boehm KA; Asmar L Clin Genitourin Cancer; 2006 Sep; 5(2):131-7. PubMed ID: 17026801 [TBL] [Abstract][Full Text] [Related]
24. Review and outlook for the role of paclitaxel in urothelial carcinoma. Vaughn DJ Semin Oncol; 1999 Feb; 26(1 Suppl 2):117-22. PubMed ID: 10190793 [TBL] [Abstract][Full Text] [Related]
25. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer]. Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952 [TBL] [Abstract][Full Text] [Related]
26. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269 [TBL] [Abstract][Full Text] [Related]
28. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374 [TBL] [Abstract][Full Text] [Related]
29. Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study. Keren-Rosenberg S; Muggia FM Semin Oncol; 1997 Feb; 24(1 Suppl 3):S26-9. PubMed ID: 9071337 [TBL] [Abstract][Full Text] [Related]
30. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination. Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166 [TBL] [Abstract][Full Text] [Related]
31. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. Vaughn DJ; Brown AW; Harker WG; Huh S; Miller L; Rinaldi D; Kabbinavar F Cancer; 2004 Feb; 100(4):746-50. PubMed ID: 14770430 [TBL] [Abstract][Full Text] [Related]
32. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357 [TBL] [Abstract][Full Text] [Related]
33. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266 [TBL] [Abstract][Full Text] [Related]
34. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761 [TBL] [Abstract][Full Text] [Related]
36. Management of hormone refractory prostate cancer: current standards and future prospects. Oh WK; Kantoff PW J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323 [TBL] [Abstract][Full Text] [Related]
37. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Colleoni M; Graiff C; Vicario G; Nelli P; Sgarbossa G; Pancheri F; Manente P Am J Clin Oncol; 1997 Aug; 20(4):383-6. PubMed ID: 9256895 [TBL] [Abstract][Full Text] [Related]
38. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202 [TBL] [Abstract][Full Text] [Related]
39. The current state of adjuvant therapy for breast cancer: focus on paclitaxel. Hudis CA Semin Oncol; 1999 Feb; 26(1 Suppl 2):1-5. PubMed ID: 10190778 [TBL] [Abstract][Full Text] [Related]